Pharmacogenomics Corner

Back to articles

Screening for extremely high lipoprotein (a) levels can improve cardiovascular risk prediction


Incorporation of extremely elevated lipoprotein (a) levels and/or corresponding LPA gene variants into traditional measures of cardiovascular risk assessment improved myocardial infarction (MI) and coronary heart disease (CHD) risk prediction, especially in patients classified as “intermediate risk” by traditional measures.


Kamstrup PR et al. Extreme lipoprotein (a) levels and improved cardiovascular risk prediction. J Am Coll Cardiol. 2013;61:1146–56.